Literature DB >> 2418395

Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.

N Einhorn, R C Bast, R C Knapp, B Tjernberg, V R Zurawski.   

Abstract

Serum CA 125 levels were measured preoperatively in 100 women undergoing diagnostic laparotomy for palpable adnexal masses. All 11 patients with frankly malignant nonmucinous ovarian carcinoma had serum CA 125 levels greater than 35 U/mL and nine of the 11 had serum CA 125 levels greater than 65 U/mL. If patients with mucinous and borderline lesions were included, serum CA 125 was greater than 35 U/mL in 11 of 18 and greater than 65 U/mL in nine of 18 patients. Among 14 individuals with pelvic masses and CA 125 greater than 65 U/mL, 13 had some form of gynecologic malignancy. These results suggest that CA 125 assay can be used as a diagnostic adjunct for discriminating benign from malignant pelvic masses.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2418395

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN： 0029-7844            Impact factor:   7.661


  11 in total

Review 1.  Primary fallopian tube cancer: a review of the literature.

Authors:  A C Hellström
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

2.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

3.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

4.  CA 125 secretion by peritoneal mesothelial cells.

Authors:  A M Zeillemaker; H A Verbrugh; A A Hoynck van Papendrecht; P Leguit
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

5.  Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma.

Authors:  A C Rosen; M Klein; H R Rosen; A H Graf; M Lahousen; A Reiner; N Vavra; L Auerbach
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

6.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Authors:  Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien van Haaften-Day; Laura J Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven Skates; Daniel W Chan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2007-10-24       Impact factor: 5.482

Review 7.  Current state of biomarker development for clinical application in epithelial ovarian cancer.

Authors:  Richard G Moore; Shannon MacLaughlan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

8.  Comparison of four malignancy risk indices in the detection of malignant ovarian masses.

Authors:  Erhan Aktürk; Rıza Efendi Karaca; Ibrahim Alanbay; Murat Dede; Emre Karaşahin; Müfit Cemal Yenen; Iskender Başer
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

Review 9.  Borderline ovarian tumors: a review of treatment.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

10.  Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Ivan Brandslund; Bente Lund; Sarah Mejer Sørensen; Max Petzold; Anders Jakobsen
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.